Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Gross Margin (2016 - 2026)

Ani Pharmaceuticals' Gross Margin history spans 14 years, with the latest figure at 59.42% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 154.0% to 59.42% in Q4 2025 year-over-year; TTM through Dec 2025 was 61.36%, a 209.0% increase, with the full-year FY2025 number at 61.36%, up 209.0% from a year prior.
  • Gross Margin hit 59.42% in Q4 2025 for Ani Pharmaceuticals, up from 59.01% in the prior quarter.
  • Over the last five years, Gross Margin for ANIP hit a ceiling of 64.7% in Q2 2025 and a floor of 78.44% in Q1 2021.
  • Historically, Gross Margin has averaged 51.48% across 5 years, with a median of 59.21% in 2025.
  • Biggest five-year swings in Gross Margin: crashed -13463bps in 2021 and later soared 12529bps in 2022.
  • Tracing ANIP's Gross Margin over 5 years: stood at 44.36% in 2021, then soared by 39bps to 61.45% in 2022, then fell by -3bps to 59.42% in 2023, then decreased by -3bps to 57.87% in 2024, then increased by 3bps to 59.42% in 2025.
  • Business Quant data shows Gross Margin for ANIP at 59.42% in Q4 2025, 59.01% in Q3 2025, and 64.7% in Q2 2025.